Novartis AG Sponsored ADR (NVS)
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades
Novartis is a large drugmaker with a wide-ranging portfolio. Like all drugmakers, it faces the challenge of patent expirations.
Trump meets Novartis CEO, says drugmaker building 11 US plants
U.S. President Donald Trump said he met Vas Narasimhan, the chief executive officer of Swiss drugmaker Novartis , at the White House on Wednesday.
Novartis to sell entire 71% stake in Indian unit to consortium of WaveRise Investments
Swiss pharmaceutical firm Novartis said on Friday that it would sell its entire 70.68% stake in its listed Indian unit to a consortium of WaveRise Investments, ChrysCapital and Two Infinity Partners.
Unnatural Products, Novartis sign license deal worth up to $1.7 billion for cardiovascular program
Unnatural Products said on Wednesday it has signed a licensing agreement with Novartis to develop macrocyclic peptide-based therapies for a cardiovascular program.
NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia
Novartis posts positive phase III ALIGN data for Vanrafia in IgAN, showing slower kidney decline as it eyes full approval in 2026.
Novartis Says Vanrafia Drug Slows Kidney Function Decline
The pharma major said that phase 3 trials showed Vanrafia slowed the decline in kidney function for adults with progressive autoimmune kidney disease, IgA nephropathy.
Novartis: Value Price, Growth Pipeline
Novartis (NVS) offers a compelling value opportunity with EPS growth, margin expansion, and a robust pipeline at a discounted multiple. NVS is undergoing a slow re-rating, actively buying back shares, and expects seven key clinical readouts in the coming months. Q4 2025 showed strong core operating profit and margin, but revenue missed due to generic competition for Entresto and Promacta.
Novartis AG (NVS) Q4 2025 Earnings Call Transcript
Novartis AG (NVS) Q4 2025 Earnings Call Transcript
Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales
NVS tops Q4 EPS estimates as margins expand, but revenues miss the mark amid U.S. generics hitting Entresto and Promacta, reshaping its growth mix.
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Novartis Sales Rise Despite Generic Drug Competition in U.S.
The pharma major said it had strong results in 2025, but guided toward a decline in core operating profit this year.
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
